Cullen/Frost Bankers, Inc. Cytokinetics Inc Transaction History
Cullen/Frost Bankers, Inc.
- $7.02 Billion
- Q1 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 142 shares of CYTK stock, worth $5,207. This represents 0.0% of its overall portfolio holdings.
Number of Shares
142Holding current value
$5,207% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
404Shares Held
116MCall Options Held
3.46MPut Options Held
1.86M-
Black Rock Inc. New York, NY14.7MShares$538 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$437 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.8MShares$394 Million0.31% of portfolio
-
State Street Corp Boston, MA6.17MShares$226 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.84MShares$104 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.45B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...